Racemetyrosine is under clinical development by Tyme and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Racemetyrosine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Racemetyrosine (SM-88) is under development for the treatment of prostate cancer, relapsed or highly refractory diseases including HR positive, HER2 negative breast cancer, metastatic pancreatic cancer, Ewing sarcoma, non-small cell lung cancers, glioblastoma, renal cancer, thyroid cancer, colon cancer, hodgkin’s lymphoma, non-hodgkin’s lymphoma, head and neck cancer, ovarian cancer and soft-tissue sarcoma. It was also under development for the treatment of breast cancer as a transdermal administration and osteosarcoma. It is a small molecule administered through oral, nasal, and parenteral routes. It acts by targeting tyrosine hydroxylase, melanin, p450 3A4 and leucine aminopeptidase.
For a complete picture of Racemetyrosine’s drug-specific PTSR and LoA scores, buy the report here.